Delaet Ingrid sold $354K of NBIX
Delaet Ingrid (Chief Regulatory Officer) sold 2,261 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $156.71 ($0.35M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This adds a datapoint on insider behavior but does not introduce new company-specific fundamentals (no trial, approval, guidance, or legal/regulatory event mentioned).
Market read
Traders may note the insider sale for sentiment, but 10b5-1 typically limits tradable informational edge.
What to watch
Insider sale size vs. total holdings is not provided beyond post-transaction shares; without context on prior sales cadence, the signal is weak.
Background
SEC Form 4 disclosure of an officer’s transaction in the issuer’s common stock.
Ticker impact
Neurocrine Biosciences insider (Chief Regulatory Officer) sold $354.3K of NBIX shares via an open-market sale under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven and small unless paired with other catalysts.
Form 4 provides a transaction datapoint without new operational/clinical/regulatory information; 10b5-1 indicates planned execution rather than new negative information.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1, it may reflect routine liquidity planning rather than a view on fundamentals.
Key entities
- issuerNeurocrine Biosciences, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderDelaet Ingrid
Chief Regulatory Officer who sold NBIX shares under a Rule 10b5-1 plan.
